Finding needles in haystacks: OMass unveils pipeline aimed at tough-to-drug targets

Published

November 17, 2021

Finding needles in haystacks: OMass unveils pipeline aimed at tough-to-drug targets

There’s not yet proof of the pudding, but OMass Therapeutics Ltd.’s new structure-based technology has passed a key test, in enabling the discovery of orally available small…

MORERelated News
Novel drug-discovery approach lands big backers
UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare...
OMass Therapeutics: The 21st Century Vertex?
Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros...
No ‘easy targets’ for Omass, which adds $95M series B for small-molecule work
OMass Therapeutics Ltd. has raised £75.5 million (US$94.6 million) in a series B round, as it continues to advance five...